Movatterモバイル変換


[0]ホーム

URL:


SG11201804166YA - Materials and methods for treatment of titin-based myopathies and other titinopaties - Google Patents

Materials and methods for treatment of titin-based myopathies and other titinopaties

Info

Publication number
SG11201804166YA
SG11201804166YASG11201804166YASG11201804166YASG11201804166YASG 11201804166Y ASG11201804166Y ASG 11201804166YASG 11201804166Y ASG11201804166Y ASG 11201804166YASG 11201804166Y ASG11201804166Y ASG 11201804166YASG 11201804166Y ASG11201804166Y ASG 11201804166YA
Authority
SG
Singapore
Prior art keywords
international
titin
domain
methods
band
Prior art date
Application number
SG11201804166YA
Inventor
Louise Rodino-Kalapac
Rachael Potter
Original Assignee
Res Inst Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens HospitalfiledCriticalRes Inst Nationwide Childrens Hospital
Publication of SG11201804166YApublicationCriticalpatent/SG11201804166YA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111M 11111111111111111111111111111111111111111111111111111111111111R111111111111111 (10) International Publication Number WO 2017/087395 Al WIPO I PCT (43) International Publication Date 26 May 2017 (26.05.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art 21(3)) with sequence listing part of description (Rule 5.2(a)) (51) International Patent Classification: A61K 9/00 (2006.01) A61K 48/00 (2006.01) A61K 38/46 (2006.01) (21) International Application Number: PCT/US2016/062052 (22) International Filing Date: 15 November 2016 (15.11.2016) Filing Language: English (25) (26) (30) English Publication Language: Priority Data: 62/255,887 16 November 2015 (16.11.2015) US (71) Applicant: RESEARCH INSTITUTE AT NATION- WIDE CHILDREN'S HOSPITAL [US/US]; 700 Chil- dren's Drive, Room W172, Cumbus, OH 43205 (US). (72) Inventors: RODINO-KALAPAC, Louise; 4912 Bixby Ridge Drive, E. Groveport, OH 43125 (US). POTTER, Rachael; 7467 Achill Dr., Dublin, OH 43017 (US). (74) Agent: NOLAND, Greta, E.; Marshall, Gerstein & Dorun LLP, 233 S.wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (54) Title: MATERIALS AND METHODS FOR TREATMENT OF TITIN-BASED MYOPATHIES AND OTHER TITINO - PATIES I-band M-line A-band se - Nebulin 5,55.5, 555 2.S.S... 5 . 5 £ < 1.1 ye/ a -Actinin Myosin TacLTITV., ;, , a,Nrawo:u Actin Thin Filament \"Titan domain: tee N2 -B AM. PEVK eras* N2-A o kinase domain (TK) 5 FIGURE 1A I-band region A-band region M-line region a y co ro EnIENIMEECOOH Myosin MyBPC Calpan-1 -0-crystalin oactinin HSP27 Nebulin „I m P D P I r sirl -FHL1 Filamin c uuscunn -DRAUFHL2 sAnk 1 PKG T-cap/Tolothonin -PKA Z-disk region 1 6.1 illnailnlkillSignigliinigniniainnilinn 013-crYstalin S100A1 HSP27 Actin Smyd2-mHSP90 Nebulin i C g ain3/p94 -Calpain-1 -Tropomyosin MARPs: CARP nig-like domain /Z-repeat 1PEVK element _Protein binding site DARR IFN3 domain X12-bus finterdoman section Kinase domain I. Ankrd-2/arpp W O 20 17 /087 395 Al i m - yi tcunn -L Lamm CalpainMp94 M B i r itiein -Mvmesin ca gt ir rL2 Nbr1Ip62 MUR I FT F-I FIGURE 113 (57) : The present application provides materials and methods for treating a patient with a titin-based myopathy, particu- larly a titin-based cardiomyopathy, and/or other titinopathy. In addition, the present application provides materials and methods for editing the titin gene in a cell by genome editing.
SG11201804166YA2015-11-162016-11-15Materials and methods for treatment of titin-based myopathies and other titinopatiesSG11201804166YA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201562255887P2015-11-162015-11-16
PCT/US2016/062052WO2017087395A1 (en)2015-11-162016-11-15Materials and methods for treatment of titin-based myopathies and other titinopaties

Publications (1)

Publication NumberPublication Date
SG11201804166YAtrue SG11201804166YA (en)2018-06-28

Family

ID=58717720

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201804166YASG11201804166YA (en)2015-11-162016-11-15Materials and methods for treatment of titin-based myopathies and other titinopaties

Country Status (16)

CountryLink
US (2)US11617783B2 (en)
EP (1)EP3377042A4 (en)
JP (3)JP7418957B2 (en)
KR (1)KR20180081600A (en)
CN (1)CN108463211B (en)
AU (1)AU2016358172B2 (en)
BR (1)BR112018009954A2 (en)
CA (1)CA3005633C (en)
CO (1)CO2018006133A2 (en)
EA (1)EA201891192A1 (en)
HK (1)HK1257955A1 (en)
IL (1)IL259441B2 (en)
MX (1)MX2018006116A (en)
NZ (2)NZ782095A (en)
SG (1)SG11201804166YA (en)
WO (1)WO2017087395A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP3613852A3 (en)2011-07-222020-04-22President and Fellows of Harvard CollegeEvaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en)2013-08-092015-02-12President And Fellows Of Harvard CollegeMethods for identifying a target site of a cas9 nuclease
US9359599B2 (en)2013-08-222016-06-07President And Fellows Of Harvard CollegeEngineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en)2013-09-062016-01-05President And Fellows Of Harvard CollegeSwitchable gRNAs comprising aptamers
US9526784B2 (en)2013-09-062016-12-27President And Fellows Of Harvard CollegeDelivery system for functional nucleases
US9322037B2 (en)2013-09-062016-04-26President And Fellows Of Harvard CollegeCas9-FokI fusion proteins and uses thereof
US11053481B2 (en)2013-12-122021-07-06President And Fellows Of Harvard CollegeFusions of Cas9 domains and nucleic acid-editing domains
EP3177718B1 (en)2014-07-302022-03-16President and Fellows of Harvard CollegeCas9 proteins including ligand-dependent inteins
SG10202104041PA (en)2015-10-232021-06-29Harvard CollegeNucleobase editors and uses thereof
WO2018027078A1 (en)2016-08-032018-02-08President And Fellows Of Harard CollegeAdenosine nucleobase editors and uses thereof
WO2018031683A1 (en)2016-08-092018-02-15President And Fellows Of Harvard CollegeProgrammable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en)2016-08-242018-03-01President And Fellows Of Harvard CollegeIncorporation of unnatural amino acids into proteins using base editing
EP3526320A1 (en)2016-10-142019-08-21President and Fellows of Harvard CollegeAav delivery of nucleobase editors
US10745677B2 (en)2016-12-232020-08-18President And Fellows Of Harvard CollegeEditing of CCR5 receptor gene to protect against HIV infection
EP3592381A1 (en)2017-03-092020-01-15President and Fellows of Harvard CollegeCancer vaccine
EP3592853A1 (en)2017-03-092020-01-15President and Fellows of Harvard CollegeSuppression of pain by gene editing
JP2020510439A (en)2017-03-102020-04-09プレジデント アンド フェローズ オブ ハーバード カレッジ Base-editing factor from cytosine to guanine
WO2018176009A1 (en)2017-03-232018-09-27President And Fellows Of Harvard CollegeNucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en)2017-05-122018-11-15President And Fellows Of Harvard CollegeAptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN111801345A (en)2017-07-282020-10-20哈佛大学的校长及成员们Methods and compositions using an evolved base editor for Phage Assisted Continuous Evolution (PACE)
WO2019139645A2 (en)2017-08-302019-07-18President And Fellows Of Harvard CollegeHigh efficiency base editors comprising gam
CA3082251A1 (en)2017-10-162019-04-25The Broad Institute, Inc.Uses of adenosine base editors
EP3724214A4 (en)2017-12-152021-09-01The Broad Institute Inc. SYSTEMS AND PROCEDURES FOR PREDICTING REPAIR RESULTS IN GENE ENGINEERING
MY209273A (en)2018-01-312025-06-30Res Inst Nationwide Childrens HospitalGene therapy for limb-girdle muscular dystrophy type 2c
US12157760B2 (en)2018-05-232024-12-03The Broad Institute, Inc.Base editors and uses thereof
CA3105216A1 (en)*2018-06-292020-01-02Research Institute At Nationwide Children's HospitalRecombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
US12281338B2 (en)2018-10-292025-04-22The Broad Institute, Inc.Nucleobase editors comprising GeoCas9 and uses thereof
US12351837B2 (en)2019-01-232025-07-08The Broad Institute, Inc.Supernegatively charged proteins and uses thereof
AU2020229340A1 (en)2019-02-262021-09-16Research Institute At Nationwide Children's HospitalAdeno-associated virus vector delivery of B-sarcoglycan and the treatment of muscular dystrophy
WO2020191246A1 (en)2019-03-192020-09-24The Broad Institute, Inc.Methods and compositions for editing nucleotide sequences
US12258573B2 (en)2019-08-212025-03-25Research Institute At Nationwide Children's HospitalAdeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
WO2021072328A1 (en)2019-10-102021-04-15The Broad Institute, Inc.Methods and compositions for prime editing rna
AU2021267940A1 (en)2020-05-082022-12-08President And Fellows Of Harvard CollegeMethods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US12171813B2 (en)2021-02-052024-12-24Christiana Care Gene Editing Institute, Inc.Methods of and compositions for reducing gene expression and/or activity
CN113512536A (en)*2021-05-072021-10-19山东大学深圳研究院 A kit for preparing human dopamine neurons and its application
EP4219726A1 (en)2021-10-152023-08-02Research Institute at Nationwide Children's HospitalSelf-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
WO2023190935A1 (en)*2022-03-312023-10-05Modalis Therapeutics CorporationMethod for treating myopathies by targeting titin gene
US20250268992A1 (en)*2022-04-252025-08-28The Jackson LaboratoryMethods for treating dilated cardiomyopathy and pharmaceutical compositions therefor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5173414A (en)1990-10-301992-12-22Applied Immune Sciences, Inc.Production of recombinant adeno-associated virus vectors
WO1995013392A1 (en)1993-11-091995-05-18Medical College Of OhioStable cell lines capable of expressing the adeno-associated virus replication gene
PT733103E (en)1993-11-092004-07-30Targeted Genetics Corp CREATION OF HIGH RECOMBINANT AAV VECTOR TITLES
US5658785A (en)1994-06-061997-08-19Children's Hospital, Inc.Adeno-associated virus materials and methods
US5856152A (en)1994-10-281999-01-05The Trustees Of The University Of PennsylvaniaHybrid adenovirus-AAV vector and methods of use therefor
JPH10511264A (en)1994-12-061998-11-04ターゲティッド ジェネティックス コーポレイション Packaging cell lines for the production of high titer recombinant AAV vectors
FR2737730B1 (en)1995-08-101997-09-05Pasteur Merieux Serums Vacc PROCESS FOR PURIFYING VIRUSES BY CHROMATOGRAPHY
CA2230655C (en)1995-08-302008-06-17Genzyme CorporationChromatographic purification of adenovirus and aav
JPH11514853A (en)1995-09-081999-12-21ジエンザイム コーポレイション Improved AAV vector for gene therapy
US5910434A (en)1995-12-151999-06-08Systemix, Inc.Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
EP1009808B1 (en)1997-09-052012-12-05Genzyme CorporationMethods for generating high titer helper-free preparations of recombinant aav vectors
US6258595B1 (en)1999-03-182001-07-10The Trustees Of The University Of PennsylvaniaCompositions and methods for helper-free production of recombinant adeno-associated viruses
CA2406743A1 (en)2000-04-282001-11-08The Trustees Of The University Of PennsylvaniaRecombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
WO2007049095A1 (en)*2005-10-252007-05-03CellectisLaglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
KR101240487B1 (en)*2006-11-092013-03-08더 존스 홉킨스 유니버시티Dedifferentiation of adult mammalian cardiomyocytes into cardiac stem cells
US20110023139A1 (en)*2008-12-042011-01-27Sigma-Aldrich Co.Genomic editing of genes involved in cardiovascular disease
FR2962041B1 (en)2010-07-012012-07-27Genethon INHIBITORS OF CALPAIN 3 FOR THE TREATMENT OF MUSCULAR DYSTROPHIES AND CARDIOMYOPATHIES
FI3597749T3 (en)2012-05-252023-10-09Univ California METHODS AND COMPOSITIONS FOR RNA-DIRECTED MODIFICATION OF TARGET DNA AND RNA-DIRECTED MODULATION OF TRANSCRIPTION
EP2900821B1 (en)*2012-09-252020-04-01Genzyme CorporationPeptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
IL293526A (en)2012-12-122022-08-01Harvard College Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
EP4279588A3 (en)*2012-12-122024-01-17The Broad Institute, Inc.Engineering of systems, methods and optimized guide compositions for sequence manipulation
JP2016505256A (en)2012-12-122016-02-25ザ・ブロード・インスティテュート・インコーポレイテッ CRISPR-Cas component system, method and composition for sequence manipulation
EP3011030B1 (en)2013-06-172023-11-08The Broad Institute, Inc.Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
TW201536329A (en)2013-08-092015-10-01Isis Pharmaceuticals Inc Compound and method for regulating the manifestation of dystrophic myotonic protein kinase (DMPK)
US9850497B2 (en)*2013-11-042017-12-26Regents Of The University Of MinnesotaGene targeting methods and tools
KR20160089526A (en)*2013-12-122016-07-27더 브로드 인스티튜트, 인코퍼레이티드Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components

Also Published As

Publication numberPublication date
US20230233651A1 (en)2023-07-27
EP3377042A1 (en)2018-09-26
CA3005633A1 (en)2017-05-26
JP2023184679A (en)2023-12-28
NZ782095A (en)2025-06-27
JP2018533959A (en)2018-11-22
KR20180081600A (en)2018-07-16
IL259441B1 (en)2023-09-01
US11617783B2 (en)2023-04-04
JP2022009734A (en)2022-01-14
US20180360921A1 (en)2018-12-20
EP3377042A4 (en)2019-05-29
CO2018006133A2 (en)2018-08-31
CA3005633C (en)2023-11-21
JP7418957B2 (en)2024-01-22
BR112018009954A2 (en)2018-11-13
NZ742751A (en)2025-06-27
IL259441B2 (en)2024-01-01
HK1257955A1 (en)2019-11-01
EA201891192A1 (en)2019-01-31
AU2016358172A1 (en)2018-06-07
AU2016358172B2 (en)2023-06-22
MX2018006116A (en)2019-04-04
IL259441A (en)2018-07-31
CN108463211B (en)2022-09-27
CN108463211A (en)2018-08-28
WO2017087395A1 (en)2017-05-26

Similar Documents

PublicationPublication DateTitle
SG11201804166YA (en)Materials and methods for treatment of titin-based myopathies and other titinopaties
SG11201808812RA (en)Novel aav8 mutant capsids and compositions containing same
SG11201804312RA (en)Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201804901WA (en)Compounds for the treatment of cancer and inflammatory disease
SG11201906853QA (en)Anti-rsv monoclonal antibody formulation
SG11201809344QA (en)Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201804373VA (en)Compositions and methods for immunooncology
SG11201803906PA (en)Control of cellular redox levels
SG11201907855QA (en)Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201808622SA (en)Chimeric receptors to flt3 and methods of use thereof
SG11201805709RA (en)Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201900038QA (en)Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter
SG11201809144XA (en)Materials and methods for treatment of hemoglobinopathies
SG11201808525UA (en)Anti-complement factor bb antibodies and uses thereof
SG11201907474UA (en)Compositions useful in treatment of spinal muscular atrophy
SG11201804161VA (en)Compositions comprising bacterial strains
SG11201804856VA (en)C-terminal lysine conjugated immunoglobulins
SG11201810010PA (en)Methods and compositions for treatment of concrete wash water
SG11201908560SA (en)Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201806544XA (en)Compounds and methods of treating rna-mediated diseases
SG11201804704PA (en)Compositions and methods for decreasing tau expression
SG11201803642WA (en)Bacteria-based protein delivery
SG11201408054RA (en)Pegylated oxm variants
SG11202000333UA (en)Bicyclic ketone compounds and methods of use thereof
SG11201803643TA (en)Virulence attenuated bacteria for treatment of malignant solid tumors

[8]ページ先頭

©2009-2025 Movatter.jp